Christopher Kimball

Cooley advised Nuvalence, a technology consultancy firm, on its acquisition by EY to accelerate the delivery of platform engineering, product development, and generative artificial intelligence platform-enabled services to organizations across industries and sectors.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Everbridge, a global leader in critical event management and national public warning solutions, on its definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Everbridge at approximately $1.8 billion.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Cooley advised Elroy Air, a company developing industry-first autonomous aircraft systems and cutting-edge software, revolutionizing the world of express shipping, on raising nearly $50 million in new funding.